早期结肠癌分期胸部CT对生存的影响:逆概率加权与因果图分析
这项回顾性研究纳入991例临床0或I期结肠癌患者,比较是否行分期胸部CT对生存的影响。经逆概率加权调整混杂后,两组5年限制性平均生存时间差异无统计学意义(总生存差异0.4个月,95%CI -0.8至2.1)。结论认为分期胸部CT不影响早期结肠癌患者生存,可考虑省略。
要点
- 临床0或I期结肠癌患者行分期胸部CT未显示生存获益。
- 两组5年总生存限制性平均时间差异仅0.4个月(95%CI -0.8至2.1)。
- 早期结肠癌分期检查可考虑省略胸部CT。
核心结论
- 分期胸部CT的使用未影响早期结肠癌患者的总生存、无复发生存和胸部转移无生存。
研究设计与样本
- 按是否行分期胸部CT分为两组,606例(61.2%)行胸部CT;采用逆概率加权调整因果图衍生的混杂因素。
- 主要结局为5年限制性平均生存时间(RMST),包括总生存、无复发生存和胸部转移无生存;并进行了敏感性分析。
诊断标准与关键数值
- 早期结肠癌定义为分期腹部CT上的临床0或I期。
- 5年RMST组间差异:总生存0.4个月(95%CI -0.8至2.1),无复发生存0.4个月(95%CI -1.1至2.3),胸部转移无生存0.6个月(95%CI -0.8至2.4),均无统计学意义。
- 敏感性分析(3年和10年RMST差异、排除分期中行FDG PET/CT者、因果图加入治疗决策)结果相似。
临床应用与阅片要点
- 对于临床0或I期结肠癌,分期胸部CT对生存无显著影响,可考虑从分期检查中省略。
- 胸部CT可能的机会性筛查和基线对比价值在本研究中未转化为生存获益。
局限性
- 回顾性单中心设计,可能存在选择偏倚和未测量混杂。
- 早期分期基于腹部CT,可能存在分期误差。
- 未报告胸部CT检出肺转移或合并症的具体诊断效能数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Staging chest CT has been shown to have negligible diagnostic yield for detecting lung metastases in patients with early-stage colon cancer. Nonetheless, staging chest CT may have potential survival benefits, including opportunistic screening of comorbidity and provision of a baseline examination for future comparisons. Evidence is lacking regarding the impact of staging chest CT on survival in patients with early-stage colon cancer. OBJECTIVE. The purpose of this study was to determine whether the performance of staging chest CT affects survival in patients with early-stage colon cancer. METHODS. This retrospective study included patients with early-stage colon cancer (defined as clinical stage 0 or I on staging abdominal CT) at a single tertiary hospital between January 2009 and December 2015. Patients were divided into two groups according to the presence of a staging chest CT examination. To ensure comparability between the two groups, inverse probability weighting was applied to adjust for the confounders derived from a causal diagram. The between-group differences in adjusted restricted mean survival time at 5 years were measured for overall survival, relapse-free survival, and thoracic metastasis-free survival. Sensitivity analyses were performed. RESULTS. A total of 991 patients (618 men and 373 women; median age, 64 years [IQR, 55-71 years]) were included: 606 patients (61.2%) had staging chest CT. For overall survival, the difference between groups in restricted mean survival time at 5 years was not significant (0.4 months [95% CI, -0.8 to 2.1 months]). The differences between groups in restricted mean survival at 5 years were also not significant for relapse-free survival (0.4 months [95% CI, -1.1 to 2.3 months]) and for thoracic metastasis-free survival (0.6 months [95% CI, -0.8 to 2.4 months]). Similar results were observed in sensitivity analyses that tested 3- and 10-year RMST differences, excluded patients who underwent FDG PET/CT during staging workup, and added treatment decision (surgery vs no surgery) to the causal diagram. CONCLUSION. The use of staging chest CT did not affect survival in patients with early-stage colon cancer. CLINICAL IMPACT. Staging chest CT may be omitted from the staging workup for patients with colon cancer of clinical stage 0 or I.
引用
- Lee, Lee, Park, et al. Staging Chest CT in Patients With Early-Stage Colon Cancer: Analysis of Impact on Survival Using Inverse Probability Weighting and Causal Diagram. AJR Am J Roentgenol. 2023. PMID: 37095662. doi:10.2214/AJR.22.28905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。